Wei Liu, Ying Sun, Hongmei Liu, Shucheng Hua*


Department of Respiratory Medicine, First Hospital, Jilin University, Changchun, PR China


Objective: To investigate the clinical efficacy of oxaliplatin when combined with thymosin in the treatment of lung cancer and its effects on serum T lymphocyte, the inflammatory factor, and the tumour necrosis factor. 

Methods: 120 patients with lung cancer that were admitted to the oncology department of our hospital from July 2016 to August 2017 were randomly divided into study group (60 cases) and control group (60 cases). The control group was treated with oxaliplatin injection, while the study group was treated with thymosin injections on the basis of the control group. Both groups were treated for 4 weeks. The clinical efficacy and serum levels of the T lymphocyte (CD3+, CD4+, CD8+, CD4+/CD8+), inflammatory factor: serum C-reactive protein (CRP) and interleukin-6 (IL-6), tumour necrosis factor (TNF-α) prognosis, and survival, along with the adverse reactions were compared between the two groups before and after treatment. 

Results: The total efficacy rate was 88.33% and disease control rate was 96.67% in the study group, which was significantly higher than the results of 66.67% and 86.67% seen in the control group (P<0.05). After treatment, the levels of CD3+, CD4+, CD8+, CD4+/CD8+ in the study group were found to be significantly higher than those before treatment and in the control group (P < 0.05). The levels of CD3+, CD4+, CD8+, CD4+/CD8+ in the control group were significantly lower than those before and after the treatment (P<0.05). The levels of CRP, IL-6, and TNF-α in the two groups were found to be significantly lower than those before treatment, and the study group was lower than that in the control group (P<0.05). The survival rate of the study group was significantly higher than that of the control group after 4-6 months, 7-9 months and 10-12 months of the treatment (P<0.05). The corresponding incidence rate was 8.33%, which was significantly lower than that of the control group (31.67%, P<0.05). 

Conclusion: Oxaliplatin, when combined with thymosin, in the treatment of lung cancer patients had an ideal clinical effect. It can significantly improve the immune function of patients, alleviate inflammation, and prolong the survival time of patients, with the incidence rate of the adverse reactions being low.


Oxaliplatin, thymosin, lung cancer, serum T lymphocyte, inflammatory factor, tumour necrosis factor.